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Chromatin profiling of cortical neurons identifies
individual epigenetic signatures in schizophrenia
Fedor E. Gusev1,2, Denis A. Reshetov2, Amanda C. Mitchell3, Tatiana V. Andreeva2,4, Aslihan Dincer 3,
Anastasia P. Grigorenko1,2, Gennady Fedonin2, Tobias Halene3, Maria Aliseychik2,4, Elena Filippova1, Zhiping Weng 5,
Schahram Akbarian 1,3 and Evgeny I. Rogaev1,2,4,6
Abstract
Both heritability and environment contribute to risk for schizophrenia. However, the molecular mechanisms of
interactions between genetic and non-genetic factors remain unclear. Epigenetic regulation of neuronal genome may
be a presumable mechanism in pathogenesis of schizophrenia. Here, we performed analysis of open chromatin
landscape of gene promoters in prefrontal cortical (PFC) neurons from schizophrenic patients. We cataloged cell-type-
based epigenetic signals of transcriptional start sites (TSS) marked by histone H3-K4 trimethylation (H3K4me3) across
the genome in PFC from multiple schizophrenia subjects and age-matched control individuals. One of the top-ranked
chromatin alterations was found in the major histocompatibility (MHC) locus on chromosome 6 highlighting the
overlap between genetic and epigenetic risk factors in schizophrenia. The chromosome conformation capture (3C)
analysis in human brain cells revealed the architecture of multipoint chromatin interactions between the
schizophrenia-associated genetic and epigenetic polymorphic sites and distantly located HLA-DRB5 and BTNL2 genes.
In addition, schizophrenia-specific chromatin modifications in neurons were particularly prominent for non-coding
RNA genes, including an uncharacterized LINC01115 gene and recently identified BNRNA_052780. Notably, protein-
coding genes with altered epigenetic state in schizophrenia are enriched for oxidative stress and cell motility
pathways. Our results imply the rare individual epigenetic alterations in brain neurons are involved in the pathogenesis
of schizophrenia.
Introduction
Schizophrenia (SZ) is a complex disorder with highly
variable clinical manifestations of psychotic symptoms,
such as auditory hallucinations, paranoid or bizarre
delusions, disorganized thinking, and significant social
dysfunction. Considerably higher concordance in mono-
zygotic twins than in dizygotic twins or siblings indicates
that there is a genetic component to this disease. The
genetic methods, such as linkage in pedigrees and large
scale genome-wide association studies (GWASs) have
been employed to identify the genomic loci contributing
to schizophrenia1. No robust evidence has been obtained
showing the contribution of common genetic variations in
the majority cases of SZ. Many studies have identified
genomic loci putatively associated with SZ, among which
the major histocompatibility complex (MHC) locus,
which includes the cluster of human leukocyte antigen
(HLA) genes, on chromosome 6, has emerged as the most
robust signal in many GWAS studies, along with several
other weaker signals on various chromosomes2. A recent
direct search of rare variations and de novo mutations in
protein-encoding gene regions in individuals with SZ
revealed no significant overlap for the identified mutant
genes in independent studies3–7. Collectively, few genetic
markers have been discovered, which together explain a
small proportion of the estimated genetic component. It is
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conceivable that many rare genetic variants with relatively
modest or week effects may contribute to schizophrenia
phenotype.
The human genome is decorated by numerous che-
mical modifications, jointly referred as “epigenetics”.
They include direct modifications of DNA bases (for
example, methylation of cytosines) and also changes of
histones, which form a nucleosome—a protein complex
DNA wraps around. Both of these epigenetic modifica-
tions are connected to gene expression8,9. For example,
H3K4me3 marks promoters of active genes10,11. Inter-
estingly, unlike genetic variants, epigenetic modifications
are subject to environmental factors and change during
lifetime. Therefore, epigenetics may at least partly
explain the unexplained proportion of SZ genetic
component.
Several studies have explored the epigenetic changes in
SZ comparing to controls (CTRL), but their significance
in schizophrenia neuropathology is still unclear12–15.
Some studies investigated the epigenetics of the periph-
eral blood cells, but the brain epigenomic profiling is
more relevant in the context of SZ. In particular, the
prefrontal cortex (PFC) plays a major role in cognition
and psychiatric diseases. However, brain epigenetic stu-
dies are complicated due to the heterogeneity of brain
tissues, which contain many different cell types. While
recently emerged single-cell epigenomic profiling is a very
promising approach16, sorting and analysis of whole
specific cell population allow us to investigate larger case-
control cohorts. For, example RNA binding protein fox-1
homolog 3 (NeuN) can be used to select neuronal nuclei
specifically and exclude non-neuronal brain cells from
analysis17–20.
Using epigenomic profiling of H3K4me3, which is
highly regulated in the developing and mature PFC17, we
performed outlier analysis and explored epigenetic chro-
matin variations in cortical neurons specific for patients
with SZ. We identified rare specific epigenetic variations
in neurons of schizophrenia patients. The enrichment for
rare up- or down open chromatin signals in schizophrenia
were found for a set of novel non-coding RNA genes and
genes essential in certain cellular pathways. We hypo-
thesize that such rare epigenetic variants may affect reg-
ulation of gene expression and contribute to
pathogenesis of SZ.
Materials and methods
H3K4me3 ChIP-seq data
We analyzed whole-genome ChIP-seq data obtained for
chromatin regions marked by H3K4me3-specific anti-
bodies in dorsolateral PFC neurons extracted from post-
mortem brain samples in a cohort of 16 unrelated patients
with SZ and 16 age-matched CTRL individuals. For the
accurate comparative analysis the identical experimental
and bioinformatics protocols were used to generate ChIP-
seq data for SZ and CTRL17–20 (Supplementary Table 1).
Bioinformatic analysis
For ChIP-seq data analysis, we used ChIP-seq reads
mapped to the human reference genome GRCh37 with
Bowtie221 using default parameters. We applied MACS
1.4.322 to identify 29,547 loci of H3K4me3 signal enrich-
ment in human prefrontal neuronal samples from a
cohort that includes a subset of SZ individuals23 (with
P-values of less than 1 × 10–10 against an input sample)
and simultaneously generate coverage tracks for each
sample. To account for unequal sequencing depth, we
first generated a list of promoter regions for known genes
from Ensembl v87 annotation (we collected transcrip-
tional start sites (TSSs) for all transcripts, generated 4 kbp
regions centered in TSSs and merged overlapping
regions), for each sample tallied the total number of reads
mapped to these regions, divided this tally by 107, and
then normalized the coverage at each base pair by the
resulting number. Finally, for each sample we quantified
the coverage in each of 29,547 regions as the sum of
normalized coverages at each base pair of a particular
region.
In order to detect regions enriched in H3K4me3 in
samples from patients with SZ against all CTRLs, we
selected upregulated peaks for which at least one indivi-
dual with SZ had at least a 1.5-fold change compared to
every of 16 CTRLs and with normalized coverage of at
least 5. For downregulated peaks, we selected peaks for
which at least one patient with SZ had at most a 0.5-fold
change compared to every of 16 CTRLs and every CTRL
have a normalized coverage of at least 5. In addition, we
computed the nominal P-value for each peak individually
as the probability of drawing the SZ coverage value for
normal distributions with parameters estimated from all
CTRL coverage values and required it to be less than 0.01.
In both analyses, we also excluded peaks with low map-
ping quality reads (if 75% of reads in the peak had MAPQ
< 10) and loci with low normalized coverage (<2.5). The
stringent threshold of fold change compared to all CTRL
individuals provides diminished positive rate while miss-
ing signals are expected (false negatives).
For both DAVID24 and ConsensusPathDB25 analyses,
we selected genes with TSSs of protein-coding transcripts
in close proximity (<2 kb) to one of the altered peaks. We
set false discovery rate threshold at 0.05 for this analysis.
Intersections of genetic datasets for GWASs, exome
data, and de novo mutations with epigenetic datasets for
H3K4me3 variations in individuals with SZ were analyzed.
For GWASs, we obtained raw P-values for all evaluated
variants and generated genomic sets by selecting all var-
iants with P-value < 5 × 10–8 and including 100-kb flank-
ing regions. To evaluate significance of overlap, we used
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H3K4me3 peaks that overlapped with these genomic sets
and the whole genetic variant set evaluated in the GWAS
as a background. For exome (both case-control and de
novo mutations) studies, we selected all SZ-altered peaks
close (2 kb) to the TSSs of protein-coding genes reported
in corresponding studies. We used all protein-coding
genes as a background in this analysis. For CNVs, we used
the whole genome as a background. For SZDB analysis,
we also used all protein-coding genes as a background.
We applied one-tailed Fisher’s exact test to evaluate sta-
tistical significance for overlap of up-, down- and all peaks
for both SZ14 and SZ2 groups separately (six tests per
each dataset) with false discovery rate <0.05.
Chromosomal conformation capture at the HLA-DRB9
locus
Postmortem PFC brain tissues for three SZ cases and
three CTRLs were obtained from the University of
Maryland and pair-matched for age, sex, postmortem
interval, and pH (Supplementary Table 2). In order to
detect DNA looping interactions 3C libraries were pre-
pared as previously described26. 3C primers (Supple-
mentary Table 3) were designed based on the following
criteria: (i) distance less than 200 bp from the HindIII
restriction site; (ii) 30 bp in length; (iii) GC% of 40–45%;
and (iv) melting temperature between 59 and 62 °C.
Results
Genomic regions showing outlier chromatin changes
marked by H3K4me3 in SZ
We performed comparative analysis of datasets of
H3K4me3 profiling in PFC neurons from patients with SZ
(N= 16) and CTRL individuals (N= 16; Supplementary
Table 1). Genome-wide correlation analysis demonstrated
that H3K4me3 profiles of two unrelated patients with SZ
(S10 and S11) were different (mean Pearson correlation
coefficient, PCC= 0.89) from all other individuals but
showed much higher similarity to each other (PCC= 0.97;
Supplementary Figure 1). No particular clinical pheno-
types or treatment specifically shared by these two sub-
jects have been detected in available medical records. To
exclude potential unknown confounding factors, we
separately analyzed these two samples (SZ2 group) and
another 14 individuals (SZ14 group).
To evaluate the roles of rare H3K4me3 variations, we
searched for loci with significant individual alterations in
patients with SZ with at least 1.5-fold changes in parti-
cular SZ individual compared to all control individuals
(Fig. 1) to focus on the most robust individual epigenetic
variants. For the SZ14 group we found 561 different
genomic loci, with 227 upregulated loci and 335 down-
regulated loci in SZ (one locus was simultaneously
upregulated in patient S8 and downregulated in patient
S6; Supplementary Table 4, Supplementary Figure 2). In
the SZ14 group, most of the upregulated or down-
regulated loci (89%) were observed in a single patient
only, thereby representing individual-specific alterations.
However, there were 56 loci (22 upregulated loci and 34
downregulated loci) with simultaneous alterations in at
least two samples. For the SZ2 group, we found 1,265 loci
(1,003 upregulated loci and 262 downregulated loci;
Supplementary Table 5, Supplementary Figure 3) with
196 (15%) regions simultaneously altered in both samples.
A notable example in the SZ14 group was upregulation
of the H3K4me3 peak (Fig. 1a, j) for individuals with SZ
on chromosome 2 harboring TSS for two ncRNA genes,
i.e., LINC01115 and the novel unannotated previously
gene BNRNA_052780, which is in a group of novel
ncRNA genes that we have recently discovered23. Thus,
this analysis revealed a single common neuronal marker
shared by up to 50% of individuals with SZ, which formed
a homogenous group in genome-wide correlation analysis
of H3K4me3 profiles. In addition to the LINC01115/
BNRNA_052780 locus, the top upregulated locus was
identified in the 3′ end of HLA-DRB9 (Fig. 2a) altered in
three patients with SZ. The most robust downregulated
loci included a locus on chromosome 19 in close proxi-
mity to the ncRNA RP11–678G14.3 (Fig. 1b) and on
chromosome 22, with the predicted novel ncRNA gene,
BNRNA_062360 (Fig. 1c). Each of these two down-
regulated loci was altered in four individuals with SZ.
The epigenetic roles of the HLA-locus and immunogenes in
neurons
One of the two top H3K4me3 upregulated loci in SZ
(the SZ peak) was identified in the 3′ end of the HLA-
DRB9 pseudogene located between the HLA-DRA and
HLA-DRB5 genes (Fig. 2a). This upregulation was found
in at least three men with SZ (patients S8, S9, and S14),
ages 50, 45, and 22 years old, respectively, and tended to
be male-specific (Fisher’s exact test nominal P-value=
0.02). Moreover, this locus was strongly marked by
H3K4me3 in the testis (Fig. 2b).
Interestingly, this peak was close to a cluster of single
nucleotide polymorphisms (SNPs), which are strongly
associated with SZ27 (Fig. 2c). Among these SNPs,
rs9268895 has been previously reported to have the
strongest association with SZ across the whole genome
(under identifier rs114002140) with a nominal discovery
P-value 8.28 × 10–15 28. We found that another SNP
(rs9268830) is located within the H3K4me3 SZ-peak, and
its G allele showed strong linkage to the A allele of
rs9268895 (D′= 0.964, Supplementary Figure 4b). This
H3K4me3 peak, located in the 3′ region of the HLA-DRB9
gene, is far from any TSS for any known gene in this
region (>14 kb). To elucidate the presumable chromatin
interactions in this locus, we performed 3C-analysis in
human brain samples. We anchored primers at the
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H3K4me3 peak, the GWAS significant SNP rs9268895,
promoter of the distantly located BTNL2 gene, and the
TSS of the pseudogene HLA-DRB9 to test for physical
looping interactions with genes in the region in pair-
matched postmortem PFC samples from individuals
diagnosed with SZ and CTRLs (Fig. 3a, Supplementary
Tables 2, 3). We detected four sequence-verified inter-
actions: (1) between the SZ-peak and BTNL2; (2) between
the SZ-peak and rs9268895; (3) between the SZ-peak and
the HLA-DRB9 TSS; and (4) between rs9268895 and
HLA-DRB5 (Fig. 3b). Each looping interaction was iden-
tified by sequencing in at least one of the tested individual
brain specimens. Our data indicated that the H3K4me3-
marked region in the pseudogene HLA-DRB9 formed a
physical loop with nearby genes BTNL2 and HLA-DRB5.
In addition to the HLA locus, immune response gene
regions are the most commonly genetic loci associated
with SZ and other psychiatric illnesses in GWASs29,30.
Here, we made interesting observation. We found that at
least 651 (51%) of 1289 known immunogenes
HHAT
g chr1
BNRNA_062360 NFATC2IP
PLEKHA3FKBP7RP11-678G14.3LINC01115
BNRNA_052780
SZ
CTRL
chr22c chr2d e chr16b chr19a chr2 h
SYNJ2PRKACB
chr1 chr6i
HCRTR2
f chr6
j
LINC01115 / BNRNA_052780
FKBP7
MMAT
RP11-678G14.3
NFATC2IP
PRKACB
BNRNA_062360
MCRTR2
SYNJ2
Fig. 1 Examples of alterations in chromatin loci in patients with SZ. In SZ14 group: a the top most commonly upregulated loci for the ncRNA
LINC01115 and the novel BNRNA_052780 gene (H3K4me3 peak genomic coordinates are chr2:862857–865643). b The top most commonly
downregulated loci for the RP11–678G14.3 gene (peak coordinates are chr19:21768973–21770226) and (c) the novel BNRNA_062360 gene (peak at
chr22:37720662–37721774). Examples of rare up and down peaks for (d) FKBP7 (peak at chr2:179342628–179344328), (e) NFATC2IP (peak at
chr16:28961457–28963616), (f) HCRTR2 (peak at chr6:55038831–55041158), (g) the intron of HHAT in a single individual with schizophrenia (peak at
chr1:210542908–210543238). Examples in SZ2 group: (h) PRKACB (peak at chr1:84629405–84633144), and (i) synaptojanin 2 (SYNJ2; peak at
chr6:158401671–158404195). j Quantitative representations of peak sizes for SZ and CTRL groups for the above examples. Samples with SZ are
colored in red; control individuals are colored in blue. SZ samples with significant H3K4me3 peaks size change are marked with a star in panels a–i
and by dark read in panel j. P-values and fold changes for each SZ sample are presented in Supplementary Tables 4 and 5
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(Supplementary Note) showed the active H3K4me3-
marked chromatin state in human prefrontal cortex
neurons. Among these genes, 13 (2.0%) and 30 (4.6%)
were dysregulated in the SZ14 and SZ2 groups, respec-
tively (Supplementary Table 6).
These data suggested that immunogenes may have a
broad and direct role in neuronal function or presumable
epigenetic responses of neurons to inflammatory immune
factors.
Gene ontology and molecular pathways for epigenetically
modified SZ loci
To further elucidate whether protein-coding genes with
promoters marked by up- or downregulated loci in
patients with SZ were enriched for any particular biolo-
gical pathways or gene ontology terms31, we used
DAVID24 and ConsensusPathDB25 web services for ana-
lysis of SZ-associated H3K4me3 loci.
In the SZ14 group, ConsensusPathDB analysis (Sup-
plementary Table 7a) showed the strongest enrichment
for genes involved in response to reactive oxygen species
(false discovery rate (FDR)-adjusted P= 1.67 × 10–5) and
regulation of cell motility (FDR-adjusted P= 3.12 × 10–5;
Fig. 4a). For example, the gene for platelet-derived growth
factor receptor, beta polypeptide (PDGFRB), which
modulates the production of reactive oxygen species via
NADPH oxidases32, is down-regulated in subject S13. The
gene for one of multimerin 2 (MMRN2) isoforms, which
regulates cell motility, is up-regulated in subject S12. This
gene is located within a genomic region harboring
10q22–23 deletions, which are associated with behavioral
abnormalities33,34. The pathways for response to reactive
oxygen species and regulation of cell motility have been
associated with schizophrenia: there is evidence of oxi-
dative damage in SZ35–38 and cell motility is driven by
actin filament dynamics39, which have been linked to de
novo mutations in a recent study of patients with SZ40.
DAVID analysis revealed no statistically significant
enrichment. However, the top term was the phospholi-
pase C (PLC) pathway, particularly hypocretin (orexin,
HCRT) and hypocretin receptor 2 (HCRTR2), in a few
individuals with SZ (Supplementary Figure 2, Supple-
mentary Table 8; see Discussion).
In the SZ2 group, enrichment analysis demonstrated
remarkable enrichment for the terms synapse (FDR-
adjusted P= 2.1 × 10–7) and cell junction (FDR-adjusted
P= 4 × 10–7) using DAVID (Supplementary Table 9); with
ConsensusPathDB (Fig. 4b, Supplementary Figure 1l,
Fig. 2 Analysis of the HLA-DRB9 locus. a The H3K4me3-marked open chromatin peak at the distal 3′-region of HLA-DRB9 was upregulated in
neurons from individuals with schizophrenia (indicated by a star); peak genomic coordinates are chr6:32427120–32428371. b The transcription
activity(Illumina BodyMap 2.0 data) and chromatin state62 suggest common activity of this locus in the testis. c A cluster of significant variations from
GWAS data for schizophrenia next to the peak (18). The log Y-scale represents reported nominal P-values for variants (36,989 cases and 113,075
controls). Bottom panel: the SNPs rs9268830 (inside the peak) and rs9268895 (the most significant SNP associated with schizophrenia in GWAS data)
(19). SZ samples are marked with S prefix, control individuals are marked with C prefix. Red and blue colors indicate SZ and CTRL, respectively
Gusev et al. Translational Psychiatry           (2019) 9:256 Page 5 of 10
Supplementary Table 7b), the top terms were nervous
system development (FDR-adjusted P= 2.36 × 10–6) and
cell differentiation (FDR-adjusted P= 9.38 × 10–5). Over-
all, these terms involved cadherins and their interacting
partners, and some were markedly dysregulated in
patients S10 and S11 (Supplementary Figure 3a–c). The
difference in enrichment of gene pathways and ontology
categories between SZ2 and SZ14 groups supports the
global epigenetic reprogramming of genes for certain
pathways in the prefrontal neurons in the two
SZ2 samples. Although unknown confounding effects
cannot yet be completely ruled out, these epigenetic dif-
ferences may present a phenomenon of biological het-
erogeneity of the psychiatric disorder defined clinically
under common SZ patterns.
Notably, we linked only 48% and 60% of SZ-altered loci
to known protein-coding genes in the SZ14 and SZ2
groups, respectively, indicating that, correspondingly, 52%
and 40% of regions were not included in the pathway
analysis. Consistent with this, altered peaks were enriched
for ncRNA genes in the SZ14 group (Bonferroni adjusted
P-value= 0.007, Table 1). Thus, ncRNA genes may have a
broader role than protein-coding genes in epigenetic
alterations in SZ pathogenesis. Overall, we identified
novel loci showing alterations in active chromatin for
ncRNA genes, which may be involved in SZ. However, the
functions of these alterations have not been evaluated yet.
Integration of ChIP-seq data with high-throughput genetic
studies
Next, we sought to test whether the H3K4me3 loci
altered in neurons of individuals with SZ were enriched in
the dataset of disease loci found in high-throughput
genetic studies. The same genetic risk factors can con-
tribute to different psychiatric diseases, particularly in SZ
and affective disorders (e.g., bipolar disorder [BD] and
major depressive disorder [MDD])41. Therefore, we
downloaded the GWAS dataset reported for SZ (Schizo-
phrenia Working Group, SWG set: 36,989 individuals
with SZ and 113,075 CTRLs)27 and the GWAS data for
five major psychiatric disorders (Cross-Disorder Group,
GDG set: 33,332 cases and 27,888 controls)41. We inves-
tigated the overlap between H3K4me3 loci altered in SZ
and the lists of SNPs (and the flanking 200-kb region)
associated with psychiatric diseases. The SNP-associated
loci were selected as sites with significant (nominal P <
5 × 10–8) and suggestive (nominal P < 1 × 10–6) thresholds
(Supplementary Tables 10, 11). Comparatively, recent
brain DNA methylation studies of SZ have shown weak13
or no42 direct overlap with the same SWG data. We also
Fig. 3 Putative looping interactions in the HLA-DRB9 locus. a Schematic representation of genes near the peak and putative looping interactions
between SZ peak, SNP rs9268895, and nearby genes BTNL2, HLA-DRB9, and HLA-DRB5. b 3C experimental analysis of cells from postmortem cortical
tissues revealed at least four looping interactions. SZ schizophrenia; CON control; -L no ligase
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found a relatively modest or no sign of overlap for the
ChIP-seq and GWAS signals for psychiatric illnesses
(Supplementary Tables 10 and 11). We found nominally
significant overlap of epigenetic up- or downregulated
H3K4me3 loci and loci harboring SNPs with suggestive
associations (GWAS P < 1 × 10–6) with major depression
disorder (MDD) in the GDG set for the SZ14 (P= 0.04)
groups (Supplementary Table 11). In total, no significant
enrichment was found for a set of epigenetic SZ loci and a
set of multiple genetic loci putatively associated in
GWASs with schizophrenia, autism spectrum disorder,
attention deficit-hyperactivity disorders, or diabetes used
as a control dataset (Supplementary Table 11) for the
SZ14 group. We also found that, on a global level, the list
of SZ-associated H3K4me3 loci was not significantly
enriched by copy number variation (CNV) regions or by
genes bearing rare de novo or inherited mutations found
in SZ 3,5,6,40,43.
However, we found some specific genes showing
overlap between our set of genes with epigenetic chan-
ges and a set genes for genetic risk for SZ and other
psychiatric disorders (Supplementary Table 10). For
example, the genes encoding L-type voltage-gated cal-
cium channel subunits and dipeptidase 2 (DPEP2) were
identified in many GWASs or in both GWASs and
exome sequencing studies of SZ data (Supplementary
Figure 2c). Interestingly, among the top seven up- and
down-regulated H3K4me3 loci listed in the SZ14 group,
at least two loci (HLA and TRAF3IP2) were strongly
associated with SZ in SWG data, and a third locus
harboring the ncRNA genes was assigned to 22q13.1,
the chromosomal locus showing genetic association
with SZ and abnormal behavior-associated 22q13 dele-
tion syndrome44.
While globally the overlap with genetic data was not
significant, when we used 2,706 genes from the SZDB
database45, which includes not only GWAS data but also
genetic linkage, gene expression, protein interaction, and
convergent function genomics data, we found a nominally
significant overlap with up-regulated peaks in the SZ14
group (nominal P= 0.007) (Supplementary Table 12).
The overlap between differentially expressed genes from
SZDB and epigenetically modified genes in SZ from the
SZ14 group included the LINC01115 ncRNA gene. The
observed overlap supported the role of the identified loci
and genes in SZ etiology.
Discussion
In this study, we performed an outlier analysis of high-
resolution mapping of the open chromatin mark,
H3K4me3, which is primarily associated with active gene
promoters, in PFC neurons of patients with SZ and CTRLs.
We identified multiple loci with up- and downregulated
open chromatin in PFC neurons of patients with SZ
versus CTRL individuals. For example, a locus in the
promoter of the ncRNA LINC01115 showed elevated
H3K4me3 in half of our small set of schizophrenic
patients. According to SZDB45, LINC01115 RNA tran-
script was also reported to be upregulated in the PFC of
patients with SZ in one study46. The function of
LINC01115 is poorly characterized. This gene is located
~100 kb upstream of TMEM18, which is well-known to
associate with obesity47. A SNP in LINC01115 has been
reported to epistatically interact with TMEM1848. A
methylation state of the CpG region located in
Table 1 Enrichment of loci characterized by up and
downregulated H3K4me3 peaks in schizophrenia in
genomic regions harboring non-coding RNA genes or
regions with no Ensembl annotated genes
H3K4me3 peak category Total
peak count
SZ14 up- and down-
peaks (561)
Count Bonferroni
adjusted P-
value
Ensembl annotated genes 20546 269 1.0
Protein-coding genes 16689 157 1.0
Non-coding genes 3857 112 0.00006
No Ensembl annotated
genes (includes novel
neuronal ncRNA genes23)
9000 192 1 × 10–25
Fig. 4 Top 10 enriched gene ontology terms analyzed with
ConsensusPathDB for the SZ14 group. Terms with FDR-adjusted
P-values of less than 0.01 are highlighted in green
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LINC01115 is linked to fat mass and fat free mass49. These
reports suggest that the LINC01115 gene/locus may reg-
ulate TMEM18 expression. Body composition per se is
altered in SZ50. Most interestingly, TMEM18 modulates
the migration of neuronal precursor cells and neural stem
cells51. Notably, abnormal migration of neuronal pro-
genitor cells has was also been reported for schizophrenia
subjects52. Therefore, our analysis revealed a single
putative neuronal marker for the gene, which may be
involved in neural cell migration, shared by up to 50% of
schizophrenic individuals with SZ in our sample set.
Additional studies are needed to confirm these findings in
a larger cohort.
Using gene ontology analysis, we found that the groups
of genes with up- and downregulation of H3K4me3 loci
were statistically significantly enriched with genes for
oxidative response and regulation of cell motility in the
SZ14 group. In addition, using DAVID, we observed the
enrichment for the plasma membrane genes and cell
motility in the top categories for the SZ14 group; how-
ever, these results were not statistically significant.
Remarkably, regulation of phospholipase activity was one
of the top pathways enriched in the downregulated loci
for SZ. Phosphoinositide-phospholipase C-β1 (PLC-β1) is
abnormally expressed in SZ53,54 and knockout of PLC-β1
in mice results in SZ-like phenotypes55. Within this
pathway, receptor 1 of sphingosine 1-phosphate (S1PR1)
is involved in activation of the PLC pathway56, and acti-
vation of HCRT and HCRTR2 increases PLC activity57.
We found these genes downregulated in some patients
with SZ.
Two patients with SZ in our dataset showed global
chromatin alterations, particularly for synaptic genes, that
were distant from those in other individuals with SZ.
These data were consistent with recent independent
observations of differential DNA methylation for some
patients with SZ, which was very distant from others in SZ
cohort groups58 and with observation that a subset of
schizophrenia subjects form a separate group based on
global alteration of transcriptome59. The segregation of
SZ2 subjects from SZ14 group may be explained by dis-
tant etiology or symptomatology of SZ subtypes. Alter-
natively, it might reflect the drug effect that robustly
changed the epigenomic state in SZ2 subjects60. To
address this we showed no mix-up for the SZ2 samples
that belong two independent subjects and that H3
K4me3 signal alterations overlap with genes showing
change in expression under pharmacological induction
and treatment of schizophrenia-like symptoms in
primate-model (Supplementary Note, Supplementary
Table 13) 61.
Our data reveal no overlap between epigenetically
modified genes and genes bearing reported de novo
mutations associated with schizophrenia38. Additional
studies involving large cohorts of individuals with SZ need
to be performed in order to estimate the total contribu-
tions of de novo mutations in H3K4me3-marked regions
at risk for SZ. In total, our data demonstrated no global
overlap between the loci showing H3K4me3 up- and
down-regulation in schizophrenic subjects and
schizophrenia-associated genetic loci implied in GWAS
studies.
However, our results revealed a set of the genes showing
both neuronal chromatin alterations and genetic asso-
ciations with SZ. Notably, the region within the HLA gene
cluster in the MHC locus on chromosome 6, which is the
strongest and most common genetic risk factor for SZ27,
also appeared to be a top epigenetically modified locus in
SZ in this study. Furthermore, we demonstrated a
potential physical looping interaction between identified
region and nearby genes (HLA-DRB5 and BTNL2), which
suggests a role of novel promoter located in HLA-DRB9
pseudogene or for non-promoter effect of this
H3K4me3 signal in cortical neurons. However, if and how
these DNA interactions are associated with SZ have yet to
be studied.
Overall, in this study we demonstrated, that most of the
epigenetic variations found specifically in individuals with
SZ were rare and enriched at loci harboring non-coding
genes. Interestingly, that the top H3K4me3 marked loci
are also reported in top of genetic loci associated with
schizophrenia (HLA locus on chromosome 6 and TRA-
F3IP2 locus on chromosome 22) suggesting a potential
causative role for such epigenetic changes. Given that
many epigenetic changes are rare or private in the schi-
zophrenia subjects they may represent random epigenetic
variations that can be termed epi-mutations. We can
hypothesize that such rare epi-mutations occurring in
neurons could contribute to risk for schizophrenia. On
the other hand, given the partial overlap for the global
epigenetic alterations shared by some subjects, the subset
of epigenetic signals can be a result of certain conditions
associated with schizophrenia pathogenesis or environ-
ment, e.g. specific changes induced by drug therapy
affecting neurotransmitter signaling. Finally, the study
presents the list of novel ncRNA genes with epigenetic
changes in schizophrenia, providing the new insight for
further study of schizophrenia mechanisms.
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